SSB
ADAP

Sandy Spring Bank’s Adaptimmune Therapeutics ADAP Stock Holding History

Sandy Spring Bank’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$207 Hold
1,050
– – ﹤0.01% 1161
2024
Q4 		$566 Hold
1,050
– – ﹤0.01% 1128
2024
Q3 		$998 Hold
1,050
– – ﹤0.01% 1087
2024
Q2 		$1.02K Hold
1,050
– – ﹤0.01% 1150
2024
Q1 		$1.66K Hold
1,050
– – ﹤0.01% 1067
2023
Q4 		$833 Hold
1,050
– – ﹤0.01% 1089
2023
Q3 		$819 Buy
+1,050
New +$881 ﹤0.01% 1100

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sandy Spring Bank's ADAP Position: Q1 2025 in Review

Sandy Spring Bank held its Adaptimmune Therapeutics (ADAP) position steady in Q1 2025 at 1,050 shares worth $207. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

Sandy Spring Bank first reported a position in ADAP in Q3 2023 and has held it in 7 quarters since. The position peaked at $1.66K in Q1 2024. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Sandy Spring Bank held 1,050 shares of Adaptimmune Therapeutics worth $207 as of Q1 2025.
  • Sandy Spring Bank left its Adaptimmune Therapeutics share count unchanged in Q1 2025.
  • Adaptimmune Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1161 holding.
  • Sandy Spring Bank first reported a position in Adaptimmune Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • Sandy Spring Bank's Adaptimmune Therapeutics position peaked at $1.66K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.